1. Jung, J-H, Soh, M-S, Ahn, Y-H, et al. Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine 2016; 95: e2818.
Google Scholar | Crossref2. Cervera, R, Serrano, R, Pons-Estel, GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015; 74: 1011–1018.
Google Scholar | Crossref | Medline3. Fernández, M, Alarcón, GS, Apte, M, et al. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum 2007; 56: 614–621.
Google Scholar | Crossref | Medline4. González-Naranjo, LA, Betancur, OM, Alarcón, GS, et al. Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: data from a multiethnic Latin American cohort. Semin Arthritis Rheum 2016; 45: 675–683.
Google Scholar | Crossref | Medline5. Jiang, N, Li, M, Zhang, M, et al. Chinese SLE Treatment and Research group (CSTAR) registry: clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus. PLoS ONE 2019; 14: e0225516.
Google Scholar | Crossref6. Cobo-Ibáñez, T, Loza-Santamaría, E, Pego-Reigosa, JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum 2014; 44: 175–185.
Google Scholar | Crossref | Medline7. Fanouriakis, A, Kostopoulou, M, Cheema, K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79: 713–723.
Google Scholar | Crossref | Medline8. Deshayes, S, Khellaf, M, Zarour, A, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux. Am J Hematol 2019; 94: 1314–1324.
Google Scholar | Crossref | Medline9. Neunert, C, Terrell, DR, Arnold, DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3: 3829–3866.
Google Scholar | Crossref | Medline10. Dörner, T, Kinnman, N, Tak, PP. Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 2010; 125: 464–475.
Google Scholar | Crossref | Medline11. Chen, H, Zheng, W, Su, J, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus-a prospective pilot study. Rheumatology 2011; 50: 1640–1644.
Google Scholar | Crossref | Medline12. Ilizaliturri-Guerra, O, Uriarte-Botello, R, Pineda-Sic, RÁ, et al. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus. Rheumatol Int 2020; 40: 1717–1724.
Google Scholar | Crossref | Medline13. Petri, M, Orbai, A-M, Alarcón, GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.
Google Scholar | Crossref | Medline14. Rodeghiero, F, Stasi, R, Gernsheimer, T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386–2393.
Google Scholar | Crossref | Medline15. Lucchini, E, Zaja, F, Bussel, J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019. Haematologica 2019; 104: 1124–1135.
Google Scholar | Crossref | Medline16. MacIsaac, J, Siddiqui, R, Jamula, E, et al. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin. Transfusion 2018; 58: 2729–2735.
Google Scholar | Crossref | Medline17. Serris, A, Amoura, Z, Canouï-Poitrine, F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol 2018; 93: 424–429.
Google Scholar | Crossref | Medline18. Jiang, B, Li, T, Guo, L, et al. Efficacy and safety of rituximab in systemic lupus erythematosus and Sjögren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases. J Clin Rheumatol 2015; 21: 244–250.
Google Scholar | Crossref | Medline19. Jovancevic, B, Lindholm, C, Pullerits, R. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus 2013; 22: 664–674.
Google Scholar | SAGE Journals20. Chung, CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13: 725–732.
Google Scholar | Crossref | Medline21. Paul, F, Cartron, G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol 2019; 15: 383–389.
Google Scholar | Crossref | Medline22. Bussel, JB, Lee, CS, Seery, C, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica 2014; 99: 1264–1271.
Google Scholar | Crossref | Medline23. Chapin, J, Lee, CS, Zhang, H, et al. Gender and duration of disease differentiate responses to rituximab–dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol 2016; 91: 907–911.
Google Scholar | Crossref | Medline24. Stasi, R, Pagano, A, Stipa, E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952–957.
Google Scholar | Crossref | Medline